Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02450201 · ClinicalTrials.gov registry record · Early Phase 1
MRI With C13 Pilot Study Prostate Cancer
A Early Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT02450201 is a Early Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 5 participants.
The verdict
NCT02450201, a Early Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a pilot clinical study of hyperpolarized pyruvate (13C) injection that includes the acquisition of magnetic resonance (MR) data and will be performed in men with localized prostate cancer. Part 1: Five patients will be evaluated for reproducibility of 13C HP MR imaging measurements obtained 2-3 weeks apart with no interim treatment. Part 2: Five patients will be evaluated for the change in 13C HP MR imaging measurements after 2 months of ADT. 13C HP MR data will be acquired in two parts of the study (which can occur simultaneously): Part 1: Patients will undergo imaging at baseline and will be repeated two to three weeks later (with no intervention in the interim) to evaluate reproducibility. Part 2: Patients will undergo imaging at baseline, initiate androgen deprivation therapy, and undergo repeat imaging two months after initiation of ADT to evaluate the ability of the imaging to reflect a metabolic response to treatment. The change in pyruvate/lactate ratio and lactate levels will be measured and compared to baseline at these timepoints.
Interventions
- DRUG Pyruvate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-10-12 |
| Est. Completion | 2017-01-17 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02450201
The ClinicalTrials.gov registry entry for NCT02450201 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pyruvate is the first listed.
NCT02450201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02450201 about?
NCT02450201 is a clinical study titled "MRI With C13 Pilot Study Prostate Cancer". This is a pilot clinical study of hyperpolarized pyruvate (13C) injection that includes the acquisition of magnetic resonance (MR) data and will be performed in men with localized prostate cancer. Part 1: Five patients will be evaluated for reproducibility of 13C HP MR imaging measurements obtained ...
What is the current status of trial NCT02450201?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2016-10-12. Estimated completion is 2017-01-17.
What interventions are being tested in trial NCT02450201?
The interventions under investigation include: Pyruvate (DRUG).
Who is sponsoring clinical trial NCT02450201?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.